Corona Remedies IPO Allotment LIVE: GMP signals 28% listing pop - Check steps to track status online

The company’s superior performance is rooted in its focus on high-margin chronic and sub-chronic segments, which account for 70.1% of domestic sales and have grown rapidly (20.48% CAGR over the same period). It has approximately 27 core “engine” brands, which contribute around 72% of domestic sales during MAT June 2025. These “engine” brands include market-leading names such as Cor, Trazer, Cor9, B-29, and Myoril during MAT June 2025.
Further, around 68% of the company’s sales are derived from therapy segments such as women’s health, cardio-diabeto, pain, and urology, which grew at a combined CAGR of approximately 22.4% between MAT June 2022 and MAT June 2025.
— Nirma Bang
As of Financial Year 2025, the Indian domestic formulation market, with a market size of approximately ₹2.3 trillion, accounted for around 2% of the global pharmaceutical market. India possesses a strong ecosystem to develop and manufacture pharmaceuticals, supported by state-of-the-art facilities and skilled technical manpower.
The domestic market (consumption) recorded a healthy CAGR of 9% between Financial Years 2020 and 2025. It is expected to grow at a CAGR of 8–9%, reaching ₹3.3–3.5 trillion by Financial Year 2030, driven by rising incidences of chronic diseases, as well as increasing awareness and access to quality healthcare.
Therapeutic & Engine brand concentration: During FY23/FY24/FY25/1QFY26, the company derived 56.0% / 60.4% / 62.4% / 65.1% of its revenue, respectively, from Women’s Health, Cardio-Diabetic and Pain Management therapeutic areas. Further, it derived 65.5% / 67.7% / 72.5% / 72.3% of its FY23/FY24/FY25/1QFY26 revenue from its 27 engine brands.
Geographical concentration: During FY23/FY24/FY25/1QFY26, the company derived 96.4% / 96.6% / 96.3% / 96.3% of its revenue from the domestic market, respectively. Any decrease in demand for the company’s products in India or any inability to expand into international markets may have an adverse impact on the company’s performance.
Raw material sourcing: The company depends entirely on third-party suppliers for raw materials and does not enter into any long-term contracts with these suppliers. Any failure to procure raw materials in a timely or cost-effective manner may have an adverse impact on the company’s performance.
As of June 2025, Corona Remedies operated through a robust distribution network comprising 22 C&F agents and over 2,000 distributors across 22 States and Union Territories in India. This network is further supported by a growing field force of 2,671 medical representatives, enabling the company to engage with specialist and super-specialist healthcare professionals, who together contributed approximately 75.8% of its prescription volume as of MAT June 2025.
According to the Crisil Intelligence Report, Corona Remedies is the second fastest growing firm among the top 30 companies in the Indian pharmaceutical market in terms of domestic sales performance from Moving Annual Total (MAT) June 2022 to June 2025. During the period, the company's domestic sales grew at a Compound Annual Growth Rate (CAGR) of 16.77 per cent compared to the IPM which grew at a CAGR of 9.21 per cent.
Corona Remedies operates two R&D facilities in India, housed within its manufacturing units, both of which are registered with the Department of Scientific and Industrial Research, Ministry of Science and Technology. As of June 30, 2025, the company employed 103 personnel in its R&D department.
The company’s research and development initiatives are currently focused on multiple projects, including:
(i) new formulation development,
(ii) enhancing efficiencies in manufacturing processes,
(iii) packaging development, and
(iv) process engineering, among other areas.
Since the Corona Remedies IPO was entirely an offer for sale, no proceeds will be received by the company and will instead go to the selling shareholders. The company via the IPO looks to achieve the benefits of listing on the stock exchanges.
1] Log in at the direct BSE link: bseindia.com/investors/appli_check.aspx
2] Select 'Equity' in the Issue Type option;
3] Select 'Corona Remedies Ltd' in the Issue Name;
4] Enter 'Application Number' or PAN card details;
5] Click on the BOX before 'I'm not a robot'; and
6] Click on the 'Search' option.
1] Log in at the direct Bigshare Services link — bigshareonline.com
2] Go to Server-1 and select 'Corona Remedies Ltd' in the company name space;
3] Select either of 'Application No./CAF No., Beneficiary ID or PAN details';
4] Enter captcha
5] Click on the 'Search' option.